Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.creatorLourenço, AP
dc.creatorFontoura, D
dc.creatorHenriques-Coelho, T
dc.creatorLeite-Moreira, AF
dc.description.abstractPulmonary hypertension (PH), increasingly recognized as a major health burden, remains underdiagnosed due mainly to the unspecific symptoms. Pulmonary arterial hypertension (PAH) has been extensively investigated. Pathophysiological knowledge derives mostly from experimental models. Paradoxically, common non-PAH PH forms remain largely unexplored. Drugs targeting lung vascular tonus became available during the last two decades, notwithstanding the disease progresses in many patients. The aim of this review is to summarize recent advances in epidemiology, pathophysiology and management with particular focus on associated myocardial and systemic compromise and experimental therapeutic possibilities. PAH, currently viewed as a panvasculopathy, is due to a crosstalk between endothelial and smooth muscle cells, inflammatory activation and altered subcellular pathways. Cardiac cachexia and right ventricular compromise are fundamental determinants of PH prognosis. Combined vasodilator therapy is already mainstay for refractory cases, but drugs directed at these new pathophysiological pathways may constitute a significant advance.
dc.subjectCiências médicas e da saúde
dc.subjectMedical and Health sciences
dc.titleCurrent pathophysiological concepts and management of pulmonary hypertension
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoFaculdade de Medicina
dc.subject.fosCiências médicas e da saúde
dc.subject.fosMedical and Health sciences
Appears in Collections:FMUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
81020.pdf959.02 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons